William E. Martin's Insider Trades & SAST Disclosures
William E. Martin's most recent trade in Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A was a trade of 986,194 Class A Common Stock done . Disclosure was reported to the exchange on March 17, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern William E. Martin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maravai LifeSciences Holdi... | William E. Martin | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 986,194 | 1,814,643 | - | - | Class A Common Stock | |
| Maravai LifeSciences Holdi... | William Martin E. | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.56 per share. | 15 Jan 2025 | 160,981 | 828,449 | - | 4.6 | 734,073 | Class A Common Stock |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,168 | 23,168 | - | - | Common Stock | |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 2,137 | 2,137 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 1,682 | 6,116 (0%) | 0% | 93.6 | 157,452 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 169 | 169 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 133 | 4,434 (0%) | 0% | 93.6 | 12,450 | Class A common stock |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 12,535 | 12,535 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 5,620 | 5,620 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 3,883 | 4,301 (0%) | 0% | 34.8 | 134,973 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 520 | 520 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 359 | 418 (0%) | 0% | 34.8 | 12,479 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 99 | 99 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 03 Jan 2022 | 59 | 59 (0%) | 0% | 27.3 | 1,612 | Class A common stock |
| KalVista Pharmaceuticals Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 10,000 | 10,000 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 12,000 | 12,000 | - | - | Director Stock Option (right to buy) | |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2020 | 24,000 | 24,000 | - | - | Stock Option (right to buy Common Stock) | |
| KalVista Pharmaceuticals Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 7,000 | 7,000 | - | - | Director Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2020 | 6,300 | 6,300 | - | - | Stock Option (right to buy) | |
| Inozyme Pharma Inc | Martin William Edwards | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2020 | 9,367 | 9,367 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges